# methods-audit — claim c29e568cf9abe52848a3e7dd5441b19f8d923c99ff01a074af371a6557e27565

Claim: Abstract extract PMID 41496424 ("HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial."):  Key fragments: associated with age, hormone receptor (HR) status, or any other clinicopathological variable analyzed. The log HER2/CEP17 ratio significantly | associated with improved EFS (adjusted HR = 0.795; p = 0.3537). A pCR prediction model including HER2/CEP17 ratio, treatment arm, and HR stat Abstract-only SHA-256 TITLE+PMID+ABSTRACT=bfc11f444d1fdea309ed186130b94ac391236512e46a5df972dee706671a9419. Not treatment advice.
Source: PMID 41496424 (https://pubmed.ncbi.nlm.nih.gov/41496424/)
Checked: 2026-09-25T08:41:41.343Z

## Method
1. Fetched abstract via NCBI efetch.
2. Checklist audit (qwen3:8b, temp 0): design in source: not stated; design matches claim: false; endpoint matches: n/a; population matches: n/a; contradiction: true.
3. Notes: The claim states that the HER2/CEP17 ratio is associated with pCR and that the log HER2/CEP17 ratio significantly associated with improved EFS (adjusted HR = 0.795; p = 0.3537). However, the source abstract clearly states that higher HER2/CEP17 ratios were not associated with improved EFS (adjusted HR = 0.795; p = 0.3537). The claim incorrectly interprets the p-value as significant, but the p-value of 0.3537 is not statistically significant. Therefore, the claim contradicts the source abstract.
4. Deterministic numeric grounding: missing tokens: none.

## Result
refutes (confidence 7500 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 1da9383d3eebcd7846324e530a9f7f9328437c7fa1141a830b33ed83d5c770b4